KATHERINE WOLVERTON: Open Payments
NPI 1033851282 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$919 in 60 payments from 15 companies in 2025. Trend: 2023 $350 · 2024 $906 · 2025 $919
Food & beverage: $839Education: $80
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 32 | $346 |
| UROGEN PHARMA, INC. | 6 | $142 |
| Janssen Biotech, Inc. | 5 | $138 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $42 |
| TOLMAR, INC. | 2 | $39 |
| PFIZER INC. | 2 | $31 |
| COLOPLAST CORP | 2 | $30 |
| Novartis Pharmaceuticals Corporation | 2 | $29 |
| Dendreon Pharmaceuticals LLC | 1 | $24 |
| Boston Scientific Corporation | 1 | $20 |
Products named: ORGOVYX, ERLEADA, ZUSDURI, GEMTESA, XTANDI, JELMYTO, JATENZO, Luja Coude.
Industry payments across NE — which companies pay providers there.
